Key Highlights

  • McKesson (NYSE:MCK) reported diluted EPS of USD 10.44, compared with USD 8.92, a gain of roughly 17% (calculated), on Revenue that climbed 8% to USD 110,957 million while diluted shares declined to 116.7 million.
  • STERIS (NYSE:STE) pushed adjusted EPS to USD 2.94 from USD 2.47, and its fiscal 2027 adjusted EPS outlook now spans USD 11.35 to USD 11.55, which includes around USD 0.18 linked to Tariff refunds.
  • Nareit FFO for National Healthcare Properties (NASDAQ:NHP) landed at USD 0.13 per diluted share, a 43.5% drop, whereas same store cash NOI in the senior housing operating portfolio improved 13.6%.
  • Viemed Healthcare (NASDAQ:VMD) produced USD 80.7 million of revenue, a 12.2% climb, and profit attributable to the company rose 32.0% to USD 4.6 million, which is USD 0.11 per diluted share.

McKesson (NYSE:MCK): Fewer Shares and Broader Volumes Lift Per-Share Earnings to USD 10.44

The fiscal second-quarter 2027 filing from McKesson (NYSE:MCK) is dated November 4, 2026 and covers the three months through September 30. Revenue advanced 8% to USD 110,957 million, and Operating Income went from USD 1,407 million to USD 1,604 million. Income attributable to the company totaled USD 1,218 million, up from USD 1,110 million, while the diluted share base contracted to 116.7 million from 124.4 million. Since fewer shares were outstanding, a Net Income increase near 10% (calculated) became EPS growth of about 17% (calculated). McKesson is preparing to split off its Medical-Surgical Solutions operation, and Apollo Funds committed around USD 1.25 billion in convertible preferred Equity to that unit, equating to roughly 13% ownership. A USD 5.0 billion unsecured Credit line maturing in 2031 was also put in place, and interest expense rose to USD 105 million from USD 74 million. The quarterly Dividend was lifted to USD 0.94 from USD 0.82. Half-year Buybacks reached USD 3.4 billion, with USD 4.3 billion of authorization remaining. Drug pricing and changes to the 340B program are flagged as threats, and no numeric guidance appears in the extract. Noncontrolling interests accounted for USD 78 million of income.

STERIS (NYSE:STE): Tariff Refunds Sit Inside a Lifted USD 11.35 to USD 11.55 Fiscal 2027 Outlook

STERIS (NYSE:STE) released findings for the quarter that ended September 30, 2026, on November 4, 2026. Sales increased 9% to USD 1.6 billion, while constant currency organic expansion came to 8%. On an unadjusted basis, net income reached USD 213.7 million, which equals USD 2.19 per diluted share, and the adjusted EPS figure moved up to USD 2.94 from USD 2.47. Adjustments remove amortization tied to acquisitions, costs of deals and integration, restructuring outlays and other unusual items. Tariff refunds contributed a pre-tax gain near USD 20 million, which means a portion of the USD 0.47 rise in adjusted EPS (calculated) is not recurring. Fiscal 2027 adjusted EPS guidance was pushed up from a USD 11.10 to USD 11.30 band to USD 11.35 to USD 11.55, and roughly USD 0.18 of the new figure comes from refunds collected year to date, so part of the raise is nonrecurring. Life Sciences sales jumped 18% to USD 170.6 million, whereas Capital equipment at Applied Sterilization Technologies dropped 21%, and that unit's organic growth forecast was trimmed to 6% to 7%. A second restructuring effort is expected to bring about USD 45 million in charges. Free Cash Flow for six months came in at USD 492.5 million, down from USD 527.7 million. The release does not allocate the refund impact to individual quarters.

National Healthcare Properties (NASDAQ:NHP): Unexplained 43.5% FFO Decline Amid a Senior Housing Shift

National Healthcare Properties (NASDAQ:NHP) is a self-managed REIT built around needs-based senior housing, and it published third-quarter 2026 figures on November 4, 2026. Nareit FFO per diluted share fell 43.5% to USD 0.13, and Normalized FFO dropped 29.6% to USD 0.19. Nothing in the release clarifies these drops, so their causes cannot be described here. Operating indicators improved: same store cash NOI in the portfolio rose 8.4%, and occupancy in the senior housing operating group reached 86.7%. The company is divesting outpatient medical buildings so that it becomes a senior housing-only business, and September brought the close of 30 sales out of 86 sites, totaling about USD 198 million. Over the quarter it acquired 22 senior housing properties for USD 300 million, with roughly USD 240 million more committed under signed contracts. Debt totals about USD 851.2 million, and net Leverage dropped to 5.5 times from 8.8 times. By redeeming its Series A and Series B preferred shares, the company expects to reduce annual dividend outflows by around USD 11 million. Pending sales and purchases could close on terms different from those described.

Viemed Healthcare (NASDAQ:VMD): Sleep and Supply Growth Lift Profit Faster Than Sales, While Ventilators Stall

Viemed Healthcare (NASDAQ:VMD) supplies home medical equipment for post-acute breathing care, and its third-quarter filing was made on November 4, 2026. Sales climbed by 12.2%, reaching USD 80.7 million compared with USD 71.9 million a year before. The company credits sleep therapy, complex respiratory services and women's health offerings for the growth. Sales of equipment and supplies went up 23.7%, and ventilator rental income increased 7.4%. Operating profit grew 23.4% to USD 7.0 million, and borrowing costs dropped to USD 0.2 million from USD 0.5 million, letting net income outrun revenue. Adjusted EBITDA, a non-GAAP metric, came in at USD 17.1 million, while gross Margin slipped to 57.3% from 57.5% because lower-margin supply sales expanded. The count of ventilator patients was 12,552, only a little above 12,372 a year before and below 12,635 in the prior quarter, while PAP therapy users totaled 43,861. A Medicare national coverage determination finalized in June 2025 established medical necessity standards for home ventilators, and management warns this could materially influence the business. Payer pricing pressure and tariff exposure through vendors are further risks. The filing contains no numeric guidance. Sleep resupply patients climbed to 40,918 from 33,518, Cash at September 30, 2026 totaled USD 9.7 million.

Where Things Stand

The answer for National Healthcare Properties (NASDAQ:NHP) stays incomplete, since the release offers no cause for its 43.5% FFO decline. A move from outpatient Assets toward senior housing, plus lower debt and preferred redemptions, could account for part of it, although the release never makes that link. McKesson (NYSE:MCK) illustrates how buybacks can shrink the share count while higher interest expense eats into the benefit. STERIS (NYSE:STE) lifted its outlook, yet a one-time tariff refund sits inside that raise. Viemed Healthcare (NASDAQ:VMD) converted 12.2% revenue growth into higher profit, though ventilator patients stayed roughly flat. Fourth-quarter outpatient closings at National Healthcare Properties (NASDAQ:NHP) are the item to track.